Skip to content
Search AI Powered

Latest Stories

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

The future that TED Talks have long promised is one step closer to reality.

The future that TED Talkshavelongpromised is one step closer to reality, thanks to a new deal between pharmaceutical giant GlaxoSmithKline (GSK) and home DNA-testing kit service 23andMe.

The four-year agreement will grant GSK exclusive access to 23andMe’s database of genetic information, with the goal of developing new, targeted drugs and therapies. This isn’t the first time that 23andMe has offered its customers’ data to another organization for research, but those partnerships have previously been transparent. What does this new deal mean for genetic privacy and who will benefit from the partnership?


To privacy advocates,there’s little more alarming than the sale of genetic information. The data could be used by insurance companies to identify certain genetic markers as high-risk, leading to increased premiumseven decades after the test is performed. Law enforcement could subpoena the data from 23andMe (or any other genetic testing company) without informing the customers and without their consent. Thelaw surrounding questions of genetic privacy and ownership are in their infancy. And no genetic testing company canensure that your genetic information remains private.

But in this case, the most serious issue seems to be profit. 23andMe’s estimated 5 million customers can choose to opt out of having their DNA used in research. Those who don’t opt out have essentially donated their genome to science. But that munificence is one-sided: whatever drugs or treatments are developed using the customers’ genetic information will be sold by GSK or 23andMe for profit.

And there’s certainly profit to be made. Separate from this deal, GSK has invested $300 million in 23andMe. It’s a relative bargain for GSK, because 23andMe’s database is up to 10 times larger than other available databases, and its customers have already paid for partial sequencing — typically a major expense.

For its part, GSK is confident that the partnership will produce effective treatments, which will benefit patients across the world. To begin, they’re focusing on treatments for Parkinson’s disease based on a gene called LRRK2 that is mutated in some Parkinson’s patients.

“When you get a genetically validated target and you pursue it, it’s twice as likely to end up being a medicine,” said GSK chief science officer Hal Barron.

Previously, 23andMe had been carrying out some genetic research itself, in partnership with the National Institutes of Health (NIH)  and University of California, Los Angeles and University of Southern California.In those cases, customers could see a clear benefit in allowing research to be carried out on their genome. Just by allowing the company to use the material that the customer had already given, they felt like part of a larger solution.

“It’s one thing for NIH to ask people to donate their genome sequences for the higher good,” Peter Pitts, president of the Center for Medicine in the Public Interest, told NBC News. “But when two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down.”

More from News

Jasmine Crockett Calls Out Trump's Hypocrisy By Pointing Out How Melania Got Her Visa
Leigh Vogel/Getty Images for SiriusXM; Kayla Bartkowski/Getty Images

Jasmine Crockett Calls Out Trump's Hypocrisy By Pointing Out How Melania Got Her Visa

Texas Democratic Representative Jasmine Crockett pointed out President Donald Trump's hypocrisy on immigration considering how First Lady Melania Trump's pathway to citizenship was possible because she received an "Einstein visa," which is usually reserved for an individual with "some sort of significant achievement."

Speaking during a House Judiciary Committee hearing titled “Restoring Integrity and Security to the Visa Process,” Crockett noted that “the idea that Trump and my Republican colleagues want to restore integrity and security in the visa process is actually a joke," and harshly criticized the Trump administration's immigration crackdown and visa restrictions.

Keep ReadingShow less
Screenshots of Jennifer Griffin and Pete Hegseth
The Hill

Fox Host Comes To Reporter's Defense After Pete Hegseth Berates Her At Pentagon Briefing

Fox News' chief political analyst Brit Hume came to the defense of Fox national security reporter Jennifer Griffin after their former colleague, Defense Secretary Pete Hegseth, criticized Griffin as the reporter "who misrepresents the most intentionally what the president says” in a Pentagon news conference.

Hegseth, a former Fox News anchor, had criticized media outlets—including his former network—for what he described as unpatriotic reporting. Hegseth took particular aim at early intelligence assessments suggesting that President Donald Trump's bombing of Iran may not have significantly crippled Iran’s nuclear capabilities.

Keep ReadingShow less

Teachers Share The Questions Students Asked In Class That Broke Their Hearts

Being a teacher is a calling.

It is not for the meek or weak of heart.

Keep ReadingShow less
Screenshot of Emily Compagno
Fox News

Fox Host Slams Dem For Dropping An F-Bomb After Praising Trump For The Same Thing Just Minutes Earlier

Fox News host Emily Compagno was criticized after she praised Donald Trump's use of the "f-bomb" earlier this week before condemning Texas Democratic Representative Jasmine Crockett's use of the same word—on the same episode of her show, no less.

Trump made headlines this week after admonishing Israel and Iran for violating a ceasefire agreement he'd announced on Truth Social. Although he claimed the ceasefire had been "agreed upon," Iran fired at least six missile barrages at Israel after it was supposed to take effect.

Keep ReadingShow less
Ken Jennings; Emily Croke
@Jeopardy/Instagram

Champ's Wild Final Jeopardy Connection

In a dramatic conclusion on last Monday’s Jeopardy!, a contestant revealed a surprising relationship to the final clue's answer. Hailing from Denver, Emily Croke made it to the final write-in portion of the game show with $12,200 in earnings.

In the category of “Collections,” host Ken Jennings read the clue:

Keep ReadingShow less